Print Friendly Page

Protocol No. S0820

Phase III

Age Group Adult

Scope National

Sponsor Type National

Title A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Applicable Disease Sites Colon and Rectum

Drugs Involved eflornithine (dfmo); sulindac (exisulind)

Status Open (affiliates only)